Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement

慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力

基本信息

  • 批准号:
    10326954
  • 负责人:
  • 金额:
    $ 50.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-06-15 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT DESCRIPTION The APOBEC3 (A3) family of proteins are cellular cytidine deaminases that suppress human immunodeficiency virus type 1 (HIV-1) infection by hypermutation of viral reverse transcripts and physically blocking reverse transcription. To evade this host defense mechanism, HIV-1 expresses the virion infectivity factor (Vif), which hijacks a cellular E3 ubiquitin ligase complex and targets A3 proteins (A3F/G/H/D) for proteasome-mediated degradation. Besides degrading A3s, HIV-1 Vif also causes G2 cell cycle arrest by targeting multiple protein phosphatase 2A (PP2A) regulators (PPP2R5 proteins) for degradation. Adding to the complexity of Vif-host protein interactions, HIV-1 Vif utilizes the transcription factor CBFβ as a non-canonical cofactor, while maedi-visna virus (MVV) Vif co-opts the prolyl isomerase cyclophilin A (CypA) instead. Our goal is to establish the biochemical and structural principles for the multifaceted activities of lentiviral Vif molecules that recruit cellular factors to degrade host proteins via ubiquitin-proteasome pathways. To achieve our goal, we will use a combination of biochemical, biophysical, structural biology, and cellular functional techniques. To establish the mechanisms by which A3 proteins are targeted by the HIV-1 Vif (Aim1), we will determine high- resolution structures of the A3-Vif-E3 interaction complexes, validate these structures by structure-guided mutagenesis experiments in vitro and in vivo, and interrogate the molecular determinants of Vif/A3/E3 ligase assembly and activation. In addition, we will also study the degradation-independent mode of Vif inhibition of A3 deamination and antiviral activities. To better understand CypA-mediated formation of MVV Vif-E3 ubiquitin ligase (Aim2), we will assemble MVV Vif/CypA/E3 ligase complexes with or without A3 substrates, determine their high-resolution structures, and perform biochemical and functional validations of our structural observations. The influences of capsid proteins on the assembly and activation of MVV Vif-E3 ligase will also be investigated. To delineate the mechanisms of PPP2R5/PP2A recruitment by lentiviral Vif-E3 ubiquitin ligases (Aim3), we will investigate the effects of PPP2R5 proteins on the assemblies of the CBFβ-mediated HIV-1 Vif and CypA-mediated MVV Vif-E3 ligases, obtain high-resolution structures, and perform structure- guided validations. Our comprehensive research design provides a robust approach that will generate unprecedented insights into the diverse functions of lentiviral Vif molecules.
项目说明 APOBEC3(A3)家族蛋白是细胞胞苷脱氨酶,能抑制人 免疫缺陷病毒1型(HIV-1)通过病毒逆转录超突变和物理感染 阻止逆转录。为了逃避这种宿主防御机制,HIV-1表达了病毒粒子的传染性 因子(Vif),劫持细胞E3泛素连接酶复合体,靶向A3蛋白(A3F/G/H/D) 蛋白酶体介导的降解。除了降解A3外,HIV-1 Vif还通过以下方式导致G2细胞周期停滞 靶向多个蛋白磷酸酶2A(PP2A)调节剂(PPP2R5蛋白)进行降解。添加到 Vif与宿主蛋白相互作用的复杂性,HIV-1Vif利用转录因子Cbfβ作为非规范的 辅因子,而Maedi-Visna病毒(MVV)Vif共用Pro异构酶亲环素A(CypA)。我们的目标 是为慢病毒Vif分子的多方面活性建立生化和结构原理 通过泛素-蛋白酶体途径招募细胞因子降解宿主蛋白。为了实现我们的目标, 我们将结合使用生化、生物物理、结构生物学和细胞功能技术。至 建立A3蛋白被HIV-1 Vif(Aim1)靶向的机制,我们将确定高- A3-Vif-E3相互作用络合物的拆分结构,通过结构指导验证这些结构 Vif/A3/E3连接酶的体内外诱变实验及其分子决定因素的研究 组装和激活。此外,我们还将研究Vif抑制的非降解模式。 A3脱氨基和抗病毒活性。为了更好地了解CypA介导的MVV Vif-E3泛素的形成 连接酶(AIM2),我们将组装MVV Vif/CypA/E3连接酶复合体,有或没有A3底物,确定 它们的高分辨率结构,并对我们的结构进行生化和功能验证 观察。衣壳蛋白对MVV Vif-E3连接酶组装和激活的影响 被调查。慢病毒Vif-E3泛素对PPP2R5/PP2A募集机制的研究 连接酶(AIM3),我们将研究PPP2R5蛋白对脑血流量β介导的组装的影响。 HIV-1 Vif和CypA介导的MVV Vif-E3连接酶,获得高分辨率结构,并执行结构- 引导式验证。我们全面的研究设计提供了一种强大的方法,将产生 对慢病毒Vif分子的各种功能的前所未有的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yong Xiong其他文献

Yong Xiong的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yong Xiong', 18)}}的其他基金

Predoctoral Program in Biophysics
生物物理学博士前课程
  • 批准号:
    10628233
  • 财政年份:
    2023
  • 资助金额:
    $ 50.25万
  • 项目类别:
Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
  • 批准号:
    10640135
  • 财政年份:
    2015
  • 资助金额:
    $ 50.25万
  • 项目类别:
Recognition of Viral DNA by APOBEC3 Proteins and their Antagonization by HIV Vif
APOBEC3 蛋白对病毒 DNA 的识别及其 HIV Vif 的拮抗作用
  • 批准号:
    8992425
  • 财政年份:
    2015
  • 资助金额:
    $ 50.25万
  • 项目类别:
Recognition of Viral DNA by APOBEC3 Proteins and their Antagonization by HIV Vif
APOBEC3 蛋白对病毒 DNA 的识别及其 HIV Vif 的拮抗作用
  • 批准号:
    9079350
  • 财政年份:
    2015
  • 资助金额:
    $ 50.25万
  • 项目类别:
Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
  • 批准号:
    10600207
  • 财政年份:
    2015
  • 资助金额:
    $ 50.25万
  • 项目类别:
Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
  • 批准号:
    10774368
  • 财政年份:
    2015
  • 资助金额:
    $ 50.25万
  • 项目类别:
Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
  • 批准号:
    10414141
  • 财政年份:
    2015
  • 资助金额:
    $ 50.25万
  • 项目类别:
Mechanisms of enveloped virus tethering by tetherin and viral countermeasures
系链蛋白束缚包膜病毒的机制和病毒对策
  • 批准号:
    8824868
  • 财政年份:
    2011
  • 资助金额:
    $ 50.25万
  • 项目类别:
STRUCTURAL STUDY OF DISEASE RELATED FACTORS
疾病相关因素的结构研究
  • 批准号:
    8361650
  • 财政年份:
    2011
  • 资助金额:
    $ 50.25万
  • 项目类别:
Mechanisms of enveloped virus tethering by tetherin and viral countermeasures
系链蛋白束缚包膜病毒的机制和病毒对策
  • 批准号:
    8467997
  • 财政年份:
    2011
  • 资助金额:
    $ 50.25万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 50.25万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 50.25万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 50.25万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 50.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 50.25万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 50.25万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 50.25万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 50.25万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 50.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 50.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了